Document Detail


Treatment, prognostic factors, and outcomes in spinal cord astrocytomas.
MedLine Citation:
PMID:  23322747     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Spinal astrocytomas are rare intramedullary CNS tumors for which there is limited consensus on treatment; the importance of the extent of resection (EOR), postoperative radiotherapy, and chemotherapy remains poorly understood. We report on outcomes associated with surgery, postoperative radiotherapy, and chemotherapy in a series of patients treated at M. D. Anderson Cancer Center (MDACC) with the aim of elucidating the role of these treatments in spinal astrocytomas.
METHODS: We retrospectively reviewed charts from a series of 83 patients with histologically confirmed spinal astrocytoma treated at MDACC during 1990-2011. Data collected included patient demographic characteristics, prognostic indicators, and treatment modality at diagnosis. We analyzed overall survival (OS) and progression-free survival (PFS) for pilocytic (World Health Organization [WHO] grade I) and infiltrative (WHO grades II, III, and IV) astrocytomas, separately. Multivariate analysis was performed for the infiltrative patients but not the pilocytic patients because of a limited number of cases.
RESULTS: Higher WHO grade among all patients was associated with worse OS (P < .0001) and PFS (P = .0003). Among patients with infiltrative tumors, neither EOR nor radiotherapy was associated with a difference in outcomes in multivariate analysis; however, among patients with infiltrative astrocytomas, chemotherapy was significantly associated with improved PFS (hazard ratio = .22, P = .0075) but not OS (hazard ratio = .89, P = .83) in multivariate analysis.
CONCLUSION: WHO grade was the strongest prognostic indicator in patients with spinal cord astrocytomas. Our results also show that chemotherapy improved PFS in infiltrative astrocytomas in multivariate analysis, but neither EOR nor radiation therapy influenced outcomes in this group.
Authors:
Mohamad H Fakhreddine; Anita Mahajan; Marta Penas-Prado; Jeffrey Weinberg; Ian E McCutcheon; Vinay Puduvalli; Paul D Brown
Related Documents :
8980897 - Acute promyelocytic leukemia in the course of acromegaly: a case report.
24980687 - Long-term results after proactive management for locoregional control in patients with ...
8453597 - Unique clinical features and prognostic significance of the translocation (6;11) in acu...
3458157 - Second or subsequent remission with a disease-free survival of 5 years or longer in acu...
10815117 - Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes ...
25397587 - Safety, feasibility, and efficacy of capecitabine maintenance in patients with advanced...
Publication Detail:
Type:  Journal Article     Date:  2013-01-14
Journal Detail:
Title:  Neuro-oncology     Volume:  15     ISSN:  1523-5866     ISO Abbreviation:  Neuro-oncology     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-26     Completed Date:  2013-09-10     Revised Date:  2014-04-01    
Medline Journal Info:
Nlm Unique ID:  100887420     Medline TA:  Neuro Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  406-12     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Astrocytoma / mortality*,  pathology,  therapy
Child
Child, Preschool
Combined Modality Therapy
Female
Humans
Infant
Male
Middle Aged
Neoplasm Grading
Prognosis
Retrospective Studies
Spinal Cord Neoplasms / mortality*,  pathology,  therapy
Survival Rate
Young Adult
Grant Support
ID/Acronym/Agency:
K24 CA160777/CA/NCI NIH HHS
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluating the use of Apo-neocarzinostatin as a cell penetrating protein.
Next Document:  Association between radiation dose to neuronal progenitor cell niches and temporal lobes and perform...